TRPC6 Polyclonal Antibody, Invitrogen™

Description

• A suggested positive control is mouse lung tissue lysate
• PA5-20256 can be used with blocking peptide PEP-0392
• Trpc6 forms a receptor-activated calcium channel in the cell membrane
• The Trpc6 channel is activated by diacylglycerol and is thought to be under the control of a phosphatidylinositol second messenger system
• Activation of the Trpc6 channel occurs independently of protein kinase C and is not triggered by low levels of intracellular calcium
• Defects in the Trpc6 gene are a cause of focal segmental glomerulosclerosis 2 (FSGS2)
• Further, Trpc6 is a member of the mammalian transient receptor potential (TRP) superfamily can be divided into three major families including the &quotecanonical TRP&quote (TRPC) family
• The seven members of this family share the activation through PLC-coupled receptors and have been suggested to be components of receptor-regulated cation channels in different cell types
• Furthermore, the members of the TRPC6/6/7 subfamily can be activated by diacylglycerol (DAG) analogs, suggesting a possible mechanism of activation of these channels by PLC-coupled receptors
• When expressed in transfected cells, Trpc6 acts as a non-selective store-independent receptor-activated cation channel
• Trpc6 is activated by DAG in a PKC-independent manner and is insensitive to IP3 activation
• There is increasing evidence that Trpc6 encodes endogenous DAG-activated receptor-operated cation channels in vivo
• Diseases associated with TRPC6 include Glomerulosclerosis, Focal Segmental, 2 and Focal Segmental Glomerulosclerosis.